CALL/AMGEN/400/0.1/21.06.24 | Real-time BOERSE MUENCHEN 12:25:21 2024-06-07 EDT | ||
| 0.004 EUR | -20.00% |
|
| Current month | -37.50% | ||
| 1 month | -83.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 0.004 | -20.00% |
| 24-06-06 | 0.005 | -28.57% |
| 24-06-05 | 0.007 | +16.67% |
| 24-06-04 | 0.006 | -25.00% |
| 24-06-03 | 0.008 | 0.00% |
Real-time BOERSE MUENCHEN
Last update June 07, 2024 at 12:25 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GZ901B |
| ISIN | DE000GZ901B1 |
| Date issued | 2023-02-20 |
| Strike | 400 $ |
| Maturity | 2024-06-21 (14 Days) |
| Parity | 10 : 1 |
| Emission price | 0.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.193 € |
|---|---|
| Lowest since issue | 0.003 € |
| Spread | 0.05 € |
| Spread % | 92.59% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.7
USD
Average target price
316.3
USD
Spread / Average Target
+3.46%
- Stock Market
- Warrants
- Warrant
